VWF, Platelets and the Antiphospholipid Syndrome.

Area of Science:

• Immunology
• Hematology
• Cardiovascular Medicine

Background:

• Antiphospholipid syndrome (APS) is defined by thrombosis and/or pregnancy complications linked to persistent antiphospholipid antibodies (aPLs).
• Diagnostic criteria include lupus anticoagulant (LAC), anti-cardiolipin (aCL), and anti-β2glycoprotein I (aβ2GPI) antibodies, alongside clinical evidence of venous, arterial, or microvascular thrombosis.

Purpose of the Study:

• To explore the association between antiphospholipid antibodies (aPLs) and arterial thrombosis in Antiphospholipid Syndrome (APS).
• To investigate the role of Von Willebrand Factor (VWF) and platelet activation in aPL-mediated arterial thrombosis.
• To consider the impact of co-existing cardiovascular risk factors on thrombosis in APS patients.

Main Methods:

• Review of existing studies linking specific aPLs (LAC, aβ2GPI, aPS/PT) to arterial thrombosis.
• Examination of the proposed mechanisms involving Von Willebrand Factor (VWF) upregulation and platelet activation.
• Consideration of the influence of additional cardiovascular risk factors.

Main Results:

• Several aPLs, including LAC, aβ2GPI, and aPS/PT, are associated with arterial thrombosis.
• aPLs may elevate arterial thrombosis risk by increasing active VWF and promoting platelet activation.
• Inflammatory processes in APS and co-existing cardiovascular risk factors can further enhance thrombosis risk, particularly ischemic stroke and myocardial infarction.

Conclusions:

• Antiphospholipid antibodies (aPLs) contribute significantly to arterial thrombosis in APS through mechanisms involving VWF and platelets.
• The interplay between aPLs, VWF, platelet activation, inflammation, and cardiovascular risk factors is crucial in APS-related arterial thrombosis.
• Further research is needed to fully elucidate the precise mechanisms by which aPLs induce thrombosis.